BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Spectral Molecular Imaging, a wholly-owned subsidiary of Cascade Technologies, Inc. (OTCBB: CSDT - News), has released a letter to shareholders from Chairman and founder, Daniel L. Farkas, Ph.D. In the letter, Dr. Farkas introduces the Company's proprietary technology and its plans to develop a line of next-generation medical diagnostic devices in the field of cancer and for other medical needs:

Dear shareholders,

I'm pleased to take this opportunity to introduce you to Spectral Molecular Imaging (SMI), a development stage medical device company we established to commercialize technology that can provide very early screening for and diagnosis of cancer and other major disease. We believe SMI's products may enable doctors to save lives and improve treatment outcomes for tens of thousands of cancer patients every year.

Pursuant to an agreement we entered into as of March 8, 2010, we became a public company through a merger transaction with Cascade Technologies, Inc. In this letter, I'd like to provide some basic background on SMI's vision, technology and the important medical needs and markets we're addressing.
 

About Spectral Molecular Imaging

Spectral Molecular Imaging, Inc., a wholly-owned subsidiary of Cascade Technologies, Inc., is a development-stage, medical imaging device company. Application of SMI’s proprietary spectral-optical imaging technology - originally developed for satellite reconnaissance - is expected to advance the diagnoses of cancer and precancerous conditions. SMI is developing non-invasive imaging systems using its patented technology for improved clinical diagnostics, primarily in the field of cancer pathology.

SMI’s devices utilize high-resolution imaging, identification, and analysis of certain molecular, cellular, and tissue features via patented spectral-imaging approaches. We also intend to provide services related to our primary products, including software modules and maintenance services, and to develop optical diagnostic products that operate in conjunction with surgical and/or evaluation procedures in real time.

Our technology is expected to enable early detection and more reliable diagnosis of various diseases, including skin cancers such as melanoma, Barrett’s esophagus (a condition caused by chronic acid reflux that can lead to esophageal cancer) and lung cancer. The development of this technology is expected to significantly improve long-term patient outcomes while substantially reducing overall costs for the healthcare system. For more information, please visit http://www.spectralmi.com.

Official Website: www.spectralmi.com  |  Yahoo Finance: Cascade Technologies Profile  |  SEC Filings: Cascade Technologies